CA2554925A1 - 2-(3-substituted-aryl)amino-4-aryl-thiazoles as tyrosine kinase inhibitors - Google Patents
2-(3-substituted-aryl)amino-4-aryl-thiazoles as tyrosine kinase inhibitors Download PDFInfo
- Publication number
- CA2554925A1 CA2554925A1 CA002554925A CA2554925A CA2554925A1 CA 2554925 A1 CA2554925 A1 CA 2554925A1 CA 002554925 A CA002554925 A CA 002554925A CA 2554925 A CA2554925 A CA 2554925A CA 2554925 A1 CA2554925 A1 CA 2554925A1
- Authority
- CA
- Canada
- Prior art keywords
- optionally substituted
- methyl
- aryl
- halogen
- basic nitrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Transplantation (AREA)
- Communicable Diseases (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Cosmetics (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US54006404P | 2004-01-30 | 2004-01-30 | |
US60/540,064 | 2004-01-30 | ||
PCT/IB2005/000401 WO2005073225A1 (en) | 2004-01-30 | 2005-01-28 | 2-(3-substituted-aryl)amino-4-aryl-thiazoles as tyrosine kinase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2554925A1 true CA2554925A1 (en) | 2005-08-11 |
Family
ID=34826177
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002554925A Abandoned CA2554925A1 (en) | 2004-01-30 | 2005-01-28 | 2-(3-substituted-aryl)amino-4-aryl-thiazoles as tyrosine kinase inhibitors |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP1711497A1 (no) |
JP (1) | JP2007519711A (no) |
KR (1) | KR20060129413A (no) |
CN (1) | CN1934107A (no) |
AU (1) | AU2005209485A1 (no) |
BR (1) | BRPI0507271A (no) |
CA (1) | CA2554925A1 (no) |
IL (1) | IL177007A0 (no) |
NO (1) | NO20063861L (no) |
NZ (1) | NZ548884A (no) |
WO (1) | WO2005073225A1 (no) |
ZA (1) | ZA200606152B (no) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8088806B2 (en) | 2005-05-09 | 2012-01-03 | Achillion Pharmaceuticals, Inc. | Thiazole compounds and methods of use |
US20060281788A1 (en) | 2005-06-10 | 2006-12-14 | Baumann Christian A | Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor |
US8697716B2 (en) | 2006-04-20 | 2014-04-15 | Janssen Pharmaceutica Nv | Method of inhibiting C-KIT kinase |
US7414050B2 (en) | 2006-04-20 | 2008-08-19 | Janssen Pharmaceutica, N.V. | Inhibitors of c-fms kinase |
CA2649755C (en) * | 2006-04-20 | 2014-12-02 | Janssen Pharmaceutica N.V. | Method of inhibiting c-kit kinase |
CA2649739C (en) | 2006-04-20 | 2015-09-01 | Janssen Pharmaceutica N.V. | Inhibitors of c-fms kinase |
WO2008080134A2 (en) * | 2006-12-22 | 2008-07-03 | Rigel Pharmaceuticals, Inc. | 4-amin0-2- (hetero) arylamino-5- (hetero) arylthiazoles useful as axl inhibitors |
GB0701426D0 (en) * | 2007-01-25 | 2007-03-07 | Univ Sheffield | Compounds and their use |
BRPI0811939A2 (pt) | 2007-05-22 | 2014-11-25 | Achillion Pharmaceuticals Inc | Tiazóis substituídos por heteroarila |
JO3240B1 (ar) | 2007-10-17 | 2018-03-08 | Janssen Pharmaceutica Nv | c-fms مثبطات كيناز |
WO2009114552A1 (en) * | 2008-03-10 | 2009-09-17 | The Board Of Trustees Of The Leland Stanford Junior University | Heteroaryl compounds, compositions, and methods of use in cancer treatment |
UA103319C2 (en) | 2008-05-06 | 2013-10-10 | Глаксосмитклайн Ллк | Thiazole- and oxazole-benzene sulfonamide compounds |
US8106209B2 (en) | 2008-06-06 | 2012-01-31 | Achillion Pharmaceuticals, Inc. | Substituted aminothiazole prodrugs of compounds with anti-HCV activity |
US8546433B2 (en) | 2009-01-16 | 2013-10-01 | Rigel Pharmaceuticals, Inc. | Axl inhibitors for use in combination therapy for preventing, treating or managing metastatic cancer |
EP2736904B1 (en) * | 2011-07-27 | 2016-03-16 | AB Science | Oxazole and thiazole derivatives as selective protein kinase inhibitors (c-kit) |
CN103130792B (zh) * | 2011-11-30 | 2016-05-04 | 正大天晴药业集团股份有限公司 | 一种2-氨基噻唑类化合物 |
EP2869897A4 (en) * | 2012-07-06 | 2016-09-28 | Univ Duke | ACTIVATION OF THE TRPV4 ION CHANNEL BY PHYSICAL STIMULI AND IMPORTANT ROLE FOR TRPV4 IN ORGANIC INFLAMMATION AND JUCKREIZ |
JOP20180012A1 (ar) | 2012-08-07 | 2019-01-30 | Janssen Pharmaceutica Nv | عملية السلفنة باستخدام نونافلوروبوتانيسولفونيل فلوريد |
EP2882757B1 (en) | 2012-08-07 | 2016-10-05 | Janssen Pharmaceutica, N.V. | Process for the preparation of heterocyclic ester derivatives |
CN103254184B (zh) * | 2013-05-27 | 2015-03-18 | 湖南科技大学 | 5-取代-3-[5-羟基-4-吡喃酮-2-基-甲硫基]-4-氨基-1,2,4-三唑类化合物及其用途 |
CN103319467B (zh) * | 2013-06-15 | 2015-10-14 | 湖南科技大学 | 一种4-[5-羟基-4-吡喃酮-2-基亚甲氨基]-3-巯基-1,2,4-三唑化合物及用途 |
WO2016028325A1 (en) | 2014-08-22 | 2016-02-25 | Duke University | Trpa1 and trpv4 inhibitors and methods of using the same for organ-specific inflammation and itch |
US11229628B2 (en) | 2015-01-09 | 2022-01-25 | Duke University | TRPA1 and TRPV4 inhibitors and methods of using the same for organ-specific inflammation and itch |
US11564911B2 (en) | 2016-04-07 | 2023-01-31 | Duke University | Small molecule dual-inhibitors of TRPV4 and TRPA1 for sanitizing and anesthetizing |
EA202192575A1 (ru) | 2019-03-21 | 2022-01-14 | Онксео | Соединения dbait в сочетании с ингибиторами киназ для лечения рака |
US20220401436A1 (en) | 2019-11-08 | 2022-12-22 | INSERM (Institute National de la Santé et de la Recherche Médicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EE200000289A (et) * | 1997-10-27 | 2001-06-15 | Agouron Pharmaceuticals, Inc. | Asendatud 4-amino-tiasool-2-üüli ühendid kui tsükliinisõltuvusega kinaaside inhibiitorid |
US6262096B1 (en) * | 1997-11-12 | 2001-07-17 | Bristol-Myers Squibb Company | Aminothiazole inhibitors of cyclin dependent kinases |
BRPI0009721B8 (pt) * | 1999-04-15 | 2021-11-23 | Bristol Myers Squibb Co | Inibidores de tirosina quinase de proteína cíclica |
HN2002000156A (es) * | 2001-07-06 | 2003-11-27 | Inc Agouron Pharmaceuticals | Derivados de benzamida tiazol y composiciones farmaceuticas para inhibir la proliferacion de celulas y metodos para su utilización. |
CN100496493C (zh) * | 2001-08-13 | 2009-06-10 | 詹森药业有限公司 | 2-氨基-4,5-三取代噻唑基衍生物 |
CA2474322A1 (en) * | 2002-01-25 | 2003-07-31 | Kylix Pharmaceuticals B.V. | 4(hetero-) aryl substituted (thia-/oxa-/pyra) zoles for inhibition of tie-2 |
CN100491374C (zh) * | 2002-08-02 | 2009-05-27 | Ab科学公司 | 2-(3-氨基芳基)氨基-4-芳基-噻唑及其作为c-kit抑制剂的应用 |
JP2006526656A (ja) * | 2003-06-03 | 2006-11-24 | ノバルティス アクチエンゲゼルシャフト | 5員ヘテロ環ベースのp−38阻害剤 |
-
2005
- 2005-01-28 NZ NZ548884A patent/NZ548884A/en unknown
- 2005-01-28 BR BRPI0507271-9A patent/BRPI0507271A/pt not_active IP Right Cessation
- 2005-01-28 CN CNA2005800081898A patent/CN1934107A/zh active Pending
- 2005-01-28 EP EP05702517A patent/EP1711497A1/en not_active Withdrawn
- 2005-01-28 KR KR1020067017411A patent/KR20060129413A/ko not_active Application Discontinuation
- 2005-01-28 JP JP2006550363A patent/JP2007519711A/ja active Pending
- 2005-01-28 AU AU2005209485A patent/AU2005209485A1/en not_active Abandoned
- 2005-01-28 CA CA002554925A patent/CA2554925A1/en not_active Abandoned
- 2005-01-28 WO PCT/IB2005/000401 patent/WO2005073225A1/en active Application Filing
-
2006
- 2006-07-20 IL IL177007A patent/IL177007A0/en unknown
- 2006-07-25 ZA ZA200606152A patent/ZA200606152B/xx unknown
- 2006-08-30 NO NO20063861A patent/NO20063861L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
CN1934107A (zh) | 2007-03-21 |
BRPI0507271A (pt) | 2007-06-26 |
IL177007A0 (en) | 2006-12-10 |
ZA200606152B (en) | 2007-11-28 |
NZ548884A (en) | 2010-06-25 |
JP2007519711A (ja) | 2007-07-19 |
KR20060129413A (ko) | 2006-12-15 |
AU2005209485A1 (en) | 2005-08-11 |
WO2005073225A1 (en) | 2005-08-11 |
NO20063861L (no) | 2006-10-23 |
EP1711497A1 (en) | 2006-10-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2554925A1 (en) | 2-(3-substituted-aryl)amino-4-aryl-thiazoles as tyrosine kinase inhibitors | |
CA2494695C (en) | 2-(3-aminoaryl)amino-4-aryl-thiazoles and their use as c-kit inhibitors | |
CA2603826C (en) | Substituted oxazole derivatives and their use as tyrosine kinase inhibitors | |
CA2542909C (en) | 2-aminoaryloxazole compounds as tyrosine kinase inhibitors | |
WO2006064375A9 (en) | Aminoaryl substituted five-membered ring heterocyclic compounds for the treatment of diseases | |
US20080039466A1 (en) | 2-(3-Substituted-Aryl) Amino-4-Aryl-Thiazoles As Tyrosine Kinase Inhibitors | |
WO2007065939A1 (en) | Substituted thiazole derivatives and their uses as tyrosine kinase inhibitors | |
AU2003253195B2 (en) | 2-(3-aminoaryl)amino-4-aryl-thiazoles and their use as c-kit inhibitors | |
MXPA06008597A (en) | 2-(3-substituted-aryl)amino-4-aryl-thiazoles as tyrosine kinase inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Discontinued |
Effective date: 20121130 |